Table 3.
The immunostaining of IGF-1R, IGF-2R, ERα and ERβ in EAC, atypical hyperplasia, and control groups
| groups | n |
ERα |
ERβ |
IGF-1R |
IGF-2R |
||||
|---|---|---|---|---|---|---|---|---|---|
| Positive (%) | Strong positive(%) | Positive (%) | Strong positive(%) | Positive (%) | Strong positive(%) | Positive (%) | Strong positive(%) | ||
| Control |
22 |
22(100) |
22(100) |
13(59.09) |
3(13.64) |
14(63.64) |
1(5.0) |
16(72.72) |
10(45.45) |
| Atypical hyperplasia |
33 |
32(95.65) |
31(93.93) |
26(78.79) |
15(45.45) |
25(75.76) |
9(27.27) |
27(81.82) |
25(75.75) |
| EAC |
80 |
59(73.75) |
10(12.5) |
78(97.5) |
75(93.75) |
72(90.0) |
32(40.0) |
15(18.75) |
10(12.50) |
|
x2 |
18.961 |
92.295 |
23.444 |
62.864 |
8.953 |
10.421 |
47.424 |
43.807 |
|
| P value | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.011 | 0.005 | 0.0000 | 0.0000 | |